CAH · Cardinal Health Inc
$235.17
+3.93 (+1.70%)
At close · Aug 14
Market Cap
$54.69B
Shares
232.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jason Hollar | Chief Executive Officer | $18,976,195 |
| Aaron E. Alt | Chief Financial Officer | $6,210,035 |
| Deborah L. Weitzman | Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | $5,507,857 |
| Jessica L. Mayer | Chief Legal and Compliance Officer | $4,925,352 |
| Stephen M. Mason | Chief Executive Officer, Global Medical Products and Distribution Segment | $4,745,044 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jason Hollar | Chief Executive Officer | $25,650,709 |
| Stephen M. Mason | Chief Executive Officer, Global Medical Products and Distribution Segment | $7,335,463 |
| Aaron E. Alt | Chief Financial Officer | $6,842,001 |
| Deborah L. Weitzman | Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | $5,085,987 |
| Jessica L. Mayer | Chief Legal and Compliance Officer | $4,657,765 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jason Hollar | Chief Executive Officer | $18,783,767 |
| Aaron E. Alt | Chief Financial Officer | $6,000,648 |
| Victor L. Crawford | Former Chief Executive Officer, Pharmaceutical Segment | $4,769,604 |
| Stephen M. Mason | Chief Executive Officer, Global Medical Products and Distribution Segment | $4,415,283 |
| Jessica L. Mayer | Chief Legal and Compliance Officer | $4,399,298 |
| Deborah L. Weitzman | Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | $4,070,451 |
| Michael Kaufmann | Former Chief Executive Officer | $3,528,968 |
| Patricia M. English | Former Interim Chief Financial Officer | $1,262,749 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Kaufmann | Former Chief Executive Officer | $13,463,557 |
| Jessica L. Mayer | Chief Legal and Compliance Officer | $5,135,066 |
| Jason Hollar | Chief Executive Officer | $3,882,699 |
| Victor L. Crawford | Former Chief Executive Officer, Pharmaceutical Segment | $3,812,805 |
| Stephen M. Mason | Chief Executive Officer, Global Medical Products and Distribution Segment | $3,611,671 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Kaufmann | Former Chief Executive Officer | $12,482,378 |
| Victor L. Crawford | Former Chief Executive Officer, Pharmaceutical Segment | $4,217,827 |
| Jason Hollar | Chief Executive Officer and Former Chief Financial Officer | $3,950,860 |
| Stephen M. Mason | Chief Executive Officer, Medical Segment | $3,754,200 |
| Jessica L. Mayer | Chief Legal and Compliance Officer | $2,939,134 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Kaufmann | Chief Executive Officer | $14,217,127 |
| Victor L. Crawford | Chief Executive Officer — Pharmaceutical Segment | $4,461,178 |
| Jason Hollar | Chief Financial Officer | $4,104,253 |
| Stephen M. Mason | Chief Executive Officer — Medical Segment | $3,423,471 |
| Jessica L. Mayer | Chief Legal and Compliance Officer The amounts reported represent the aggregate accounting value of PSUs and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2022 table on page 59 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2022. The accounting values of the PSUs granted during fiscal 2022 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 15,563,620; Mr. Hollar — 3,890,880; Mr. Crawford — 3,890,880; Mr. Mason — 3,890,880; and Ms. Mayer — 3,537,225. Mr. Hollar was elected Chief Executive Officer and Mr. Kaufmann departed from the company, each effective September 1, 2022. Mr. Crawford ceased to serve as Chief Executive Officer, Pharmaceutical Segment effective September 19, 2022, and he will depart from the company on November 13, 2022. Under the standard terms of our 2011 LTIP applicable to all retirement-eligible participants, the unvested portions of these awards vest on a prorated basis when the named executive leaves the company, and the remaining portions are forfeited. Vested PSUs pay out based on actual performance. The amount shown in this column for 2022 includes RSUs with an accounting value of 1,750,003 granted to Ms. Mayer in November 2021 to move her total direct compensation closer to the median of the Comparator Group market data for chief legal officer roles. | $2,914,202 |
| David C. Evans | Former interim Chief Financial Officer | $2,205,211 |
| Jorge M. Gomez | Former Chief Financial Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2020 table on page 42 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2020. The accounting values of the PSUs granted during fiscal 2020 at target are: Mr. Kaufmann — 6,239,994; Mr. Hollar — 1,067,620; Mr. Crawford — 1,716,012; Mr. Mason — 1,404,006; and Ms. Mayer — 1,092,000. The accounting values of the PSUs granted during fiscal 2020 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,975,994; Mr. Hollar — 2,562,308; Mr. Crawford — 4,118,412; Mr. Mason — 3,369,606; and Ms. Mayer — 2,620,800. Mr. Kaufmann also served as interim Chief Financial Officer from August 9, 2019 until August 31, 2019. Mr. Hollar joined us on April 27, 2020 and became Chief Financial Officer on May 26, 2020. To address compensation forfeited at his former employer, Mr. Hollar received a sign-on bonus of 1,550,000, PSUs with an accounting value of 1,067,620 and RSUs with an accounting value of 1,000,000. He also received a 200,000 lump sum payment for relocation. He must repay the full sign-on bonus and relocation payment if he voluntarily leaves the company during the first year following his start date and 50% of it if he leaves during the second year following his start date. Mr. Mason was not previously a named executive. Mr. Evans served as interim Chief Financial Officer from September 1, 2019 until May 25, 2020. In his interim role, he received monthly cash compensation of 220,000 during his employment and did not participate in our annual or long-term incentive plans or our Severance Plan. Mr. Gomez served as Chief Financial Officer from the beginning of the fiscal year through August 8, 2019, when he left the company. | $68,525 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael Kaufmann | Chief Executive Officer | $15,571,004 |
| Victor L. Crawford | Chief Executive Officer — Pharmaceutical Segment | $6,725,822 |
| Jorge M. Gomez | Former Chief Financial Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2020 table on page 42 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2020. The accounting values of the PSUs granted during fiscal 2020 at target are: Mr. Kaufmann — 6,239,994; Mr. Hollar — 1,067,620; Mr. Crawford — 1,716,012; Mr. Mason — 1,404,006; and Ms. Mayer — 1,092,000. The accounting values of the PSUs granted during fiscal 2020 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,975,994; Mr. Hollar — 2,562,308; Mr. Crawford — 4,118,412; Mr. Mason — 3,369,606; and Ms. Mayer — 2,620,800. Mr. Kaufmann also served as interim Chief Financial Officer from August 9, 2019 until August 31, 2019. Mr. Hollar joined us on April 27, 2020 and became Chief Financial Officer on May 26, 2020. To address compensation forfeited at his former employer, Mr. Hollar received a sign-on bonus of 1,550,000, PSUs with an accounting value of 1,067,620 and RSUs with an accounting value of 1,000,000. He also received a 200,000 lump sum payment for relocation. He must repay the full sign-on bonus and relocation payment if he voluntarily leaves the company during the first year following his start date and 50% of it if he leaves during the second year following his start date. Mr. Mason was not previously a named executive. Mr. Evans served as interim Chief Financial Officer from September 1, 2019 until May 25, 2020. In his interim role, he received monthly cash compensation of 220,000 during his employment and did not participate in our annual or long-term incentive plans or our Severance Plan. Mr. Gomez served as Chief Financial Officer from the beginning of the fiscal year through August 8, 2019, when he left the company. | $3,150,779 |
| Jessica L. Mayer | Chief Legal and Compliance Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2021 table on page 61 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2021. The accounting values of the PSUs granted during fiscal 2021 at target are: Mr. Kaufmann — 6,197,813; Mr. Hollar — 1,549,439; Mr. Crawford — 1,704,422; Mr. Mason — 1,549,439; and Ms. Mayer — 1,146,595. The accounting values of the PSUs granted during fiscal 2021 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,502,892; Mr. Hollar — 3,625,709; Mr. Crawford — 3,920,149; Mr. Mason — 3,625,709; and Ms. Mayer — 2,683,059. | $2,967,035 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Kaufmann | Chief Executive Officer | $8,423,580 |
| Jorge M. Gomez | Former Chief Financial Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2020 table on page 42 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2020. The accounting values of the PSUs granted during fiscal 2020 at target are: Mr. Kaufmann — 6,239,994; Mr. Hollar — 1,067,620; Mr. Crawford — 1,716,012; Mr. Mason — 1,404,006; and Ms. Mayer — 1,092,000. The accounting values of the PSUs granted during fiscal 2020 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,975,994; Mr. Hollar — 2,562,308; Mr. Crawford — 4,118,412; Mr. Mason — 3,369,606; and Ms. Mayer — 2,620,800. Mr. Kaufmann also served as interim Chief Financial Officer from August 9, 2019 until August 31, 2019. Mr. Hollar joined us on April 27, 2020 and became Chief Financial Officer on May 26, 2020. To address compensation forfeited at his former employer, Mr. Hollar received a sign-on bonus of 1,550,000, PSUs with an accounting value of 1,067,620 and RSUs with an accounting value of 1,000,000. He also received a 200,000 lump sum payment for relocation. He must repay the full sign-on bonus and relocation payment if he voluntarily leaves the company during the first year following his start date and 50% of it if he leaves during the second year following his start date. Mr. Mason was not previously a named executive. Mr. Evans served as interim Chief Financial Officer from September 1, 2019 until May 25, 2020. In his interim role, he received monthly cash compensation of 220,000 during his employment and did not participate in our annual or long-term incentive plans or our Severance Plan. Mr. Gomez served as Chief Financial Officer from the beginning of the fiscal year through August 8, 2019, when he left the company. | $2,361,293 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anita Zielinski | Chief Accounting Officer | Appointed | 2026-08-05 |
| Gregory B. Kenny | Board of Directors | Retired | 2026-03-23 |
| Gregory B. Kenny | Board Chair | Retired | 2026-03-23 |
| Sudhakar Ramakrishna | Director | Appointed | 2025-03-10 |
| Robert W. Musslewhite | Director | Appointed | 2025-03-10 |
| Robert W. Azelby | Director | Appointed | 2024-02-28 |
| Aaron E. Alt | Chief Financial Officer ("CFO") | Appointed | 2022-12-19 |
| Victor L. Crawford | Chief Executive Officer, Pharmaceutical Segment | Resigned | 2022-09-08 |
| Sujatha Chandrasekaran | Independent Director | Appointed | 2022-09-06 |
| Christine Mundkur | Independent Director | Appointed | 2022-09-06 |
| Michelle Brennan | Independent Director | Appointed | 2022-09-06 |
| Steven Barg | Independent Director | Appointed | 2022-09-06 |
| Sujatha Chandrasekaran | new independent members of the Board | Appointed | 2022-09-06 |
| Christine A. Mundkur | new independent members of the Board | Appointed | 2022-09-06 |
| Michelle M. Brennan | new independent members of the Board | Appointed | 2022-09-06 |
| Steven K. Barg | new independent members of the Board | Appointed | 2022-09-06 |
| Patricia M. English | Interim CFO | Appointed | 2022-08-11 |
| Mary C. Scherer | Senior Vice President and Chief Accounting Officer | Appointed | 2022-08-11 |
| Michael C. Kaufmann | member of the Board | Resigned | 2022-08-11 |
| Jason M. Hollar | director | Appointed | 2022-08-11 |
| Jason M. Hollar | Chief Executive Officer | Appointed | 2022-08-11 |
Key facts
CIK
721371
CUSIP
14149Y108
13F (30d)
1320 filings
1278 filers
Visit website
Investor relations